IP Library Granted Patent US 9,029,512
Granted Patent B2
US 9,029,512 · App. 12/618,106 · Granted May 12, 2015

Anti-phospho-Akt antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,029,512
App. No.
12/618,106
Granted
May 12, 2015
Kind
B2
Abstract

The present invention relates to antibodies that immunospecifically bind to phospho-Akt and certain p-Akt substrates. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to p-Akt-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

Claims (8)

1. A monoclonal antibody which specifically binds to a phosphorylated epitope within SEQ ID NO:5 or SEQ ID NO:6 obtained by a method comprising the steps of:

a. administering to a mammal with at least two peptides, wherein the two peptides consist of the amino acid sequences of SEQ ID Nos. 5 and 6, respectively, and wherein the two peptides are phosphorylated;

b. collecting cells producing the antibody from the mammal; and

c. immortalizing the cells obtained in step (b) thereby creating a hybridoma expressing the monoclonal antibody.

2. The monoclonal antibody of claim 1 wherein the mammal is immuno-compromised and the monoclonal antibody produced is a human antibody.

3. The monoclonal antibody of claim 2 which is labeled with a detectable label.

4. The monoclonal antibody of claim 3 wherein the detectable label is a fluorescent label, a luminescent label, or a bioluminescent label.

5. The monoclonal antibody of claim 1 , wherein the two peptides are phosphorylated in at least one serine or threonine residue within the peptides.

Assignments (2)
COURT ORDER Recorded Jun 1, 2017
From: NUCLEA BIOTECHNOLOGIES, INC.
To: NMDX, LLC
Reel/Frame 042562/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2009
From: MURACA, PATRICK J
To: NUCLEA BIOMARKERS, LLC
Reel/Frame 023701/0317 →